Enovix Corporation (ENVX) Guidance & Earnings Results

On 2026-10-13 Enovix Corporation raised guidance: "Q3'26 revenue raised to ~$11.0M from $9.0-10.0M; Q3'26 non-GAAP operating loss improved to ~($29.2)M from ($29.0-32.0)M; Q3'26 capex lowered to ~$3.0M from $8.0-12.0M; Q4 orders already exceeded Q3 total…" — from its own filing, as read by EquiReason.

Source: SEC EDGAR filings · figures as of 2026-07-05 · read by EquiReason

ENVXEnovix CorporationFollow ENVX — free

Electrical Equipment & Parts · Industrials

—

Price chart with a free account

Market cap: 612.3M
P/E TTM: —
Dividend yield: —
52-week: —
Next earnings: 10 Nov, in 17 days

What management guided

each earnings 8-K · figures checked against the filing text

Release	Direction	What they said
13 Oct 26	Raised	Q3'26 revenue raised to ~$11.0M from $9.0-10.0M; Q3'26 non-GAAP operating loss improved to ~($29.2)M from ($29.0-32.0)M; Q3'26 capex lowered to ~$3.0M from $8.0-12.0M; Q4 orders already exceeded Q3 total revenue.
12 Aug 26	Raised	Q3 2026 revenue $9.0-10.0M (vs Q3 2025 $8.0M); non-GAAP loss from ops ($29.0-32.0)M; non-GAAP EPS ($0.13-0.17); capex $8.0-12.0M
5 Nov 25	Raised	Q4 2025 revenue guidance raised to $9.5-10.5M from prior $7.5-8.5M; non-GAAP loss from operations guidance improved to ($30-33M) from ($31-35M).
31 Jul 25	Raised	Q3 2025 revenue $7.5-8.5M (vs Q2 $7.5M); non-GAAP operating loss $31-35M; non-GAAP net loss per share $0.14-0.18

Enovix Corporation — questions

What guidance did Enovix Corporation give?: On 2026-10-13: "Q3'26 revenue raised to ~$11.0M from $9.0-10.0M; Q3'26 non-GAAP operating loss improved to ~($29.2)M from ($29.0-32.0)M; Q3'26 capex lowered to ~$3.0M from $8.0-12.0M; Q4 orders already exceeded Q3 total revenue."
When does Enovix Corporation report earnings?: Enovix Corporation's next earnings report is expected on 2026-11-10.

Every figure on this page comes from Enovix Corporation's own SEC filings — see them on SEC EDGAR. Price data is licensed and shown only inside the product.

How these figures are read: methodology · EquiReason.

Important information. Figures on this page are taken from filings submitted to the U.S. Securities and Exchange Commission (SEC) and processed automatically by EquiReason. They may contain errors, omissions or delays, and EquiReason makes no representation or warranty as to their accuracy, completeness or timeliness. Always verify figures against the original filing on SEC EDGAR before relying on them.

This page is provided for general information and educational purposes only. It does not constitute investment, financial, legal or tax advice, and it is not a recommendation or an offer to buy, sell or hold any security. It does not take into account your objectives, financial situation or needs. Past performance does not guarantee future results; any reliance on this information is at your own risk. See our Disclaimer and Risk Disclosure.